Form 4 for INSM INSMED Inc
Accepted 2026-07-08 16:03:40 ET · period of report 2026-07-06 · accession 0001796960-26-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-08 16:03 | 2026-07-06 | INSM | Flammer Martina M.D. | Chief Medical Off | M - OptEx | $25.80 | +12.3K | 72.8K | +20% | +$317.4K |
| DMT | 2026-07-08 16:03 | 2026-07-06 | INSM | Flammer Martina M.D. | Chief Medical Off | S - Sale+OE | $109.98 | -12.3K | 60.5K | -17% | -$1.35M |
| DMT | 2026-07-08 16:03 | 2026-07-06 | INSM | Flammer Martina M.D. | Chief Medical Off | M - OptEx | $0.00 | -12.3K | 4,358 | -74% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-06 | M | A | 7,945 | $29.13 | 68,431 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2026-07-06 | M | A | 4,357 | $19.74 | 72,788 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 3 | Common | Common Stock | 2026-07-06 | S | D | 4,854 | $109.02 | 67,934 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F2) This is the weighted average sales price representing 4,854 shares sold at prices ranging from $108.90 to $109.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 4 | Common | Common Stock | 2026-07-06 | S | D | 7,448 | $110.60 | 60,486 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F3) This is the weighted average sales price representing 7,448 shares sold at prices ranging from $110.36 to $110.71 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 5 | Derivative | Stock Option (right to buy) | 2026-07-06 | M | D | 7,945 | $0.00 | 23,835 | D | $29.13 · — to 2034-01-04 | 7,945 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 6 | Derivative | Stock Option (right to buy) | 2026-07-06 | M | D | 4,357 | $0.00 | 4,358 | D | $19.74 · — to 2033-01-05 | 4,357 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |